Otonomy Provides Business and Financial Update

Back to Jobs

Actions taken to reduce costs following suspension of OTIVIDEX™  development Non-commercial workforce reduced by one-third Current cash balance expected to fund company into 2020 Review underway to prioritize the company’s pipeline which includes multiple clinical and preclinical stage assets SAN

Apply Now